Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2018 3
2019 3
2020 5
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer.
Jandu HK, Veal CD, Fachal L, Luccarini C, Aguado-Barrera ME, Altabas M, Azria D, Baten A, Bourgier C, Bultijnck R, Colciago RR, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Elliott RM, Green S, Gutiérrez-Enríquez S, Herskind C, Lambrecht M, Monten C, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, Carmen De Santis M, Seibold P, Sperk E, Veldwijk M, Paul Symonds R, Stobart H, Taboada-Valladares B, Vega A, Veldeman L, Webb AJ, Weltens C, West CM, Rattay T, Talbot CJ; REQUITE consortium. Jandu HK, et al. Radiother Oncol. 2023 Oct;187:109806. doi: 10.1016/j.radonc.2023.109806. Epub 2023 Jul 10. Radiother Oncol. 2023. PMID: 37437607 Free article.
(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.
Rosas JC, Aguado-Barrera ME, Azria D, Briers E, Elliott R, Farcy-Jacquet MP, Giraldo A, Gutiérrez-Enríquez S, Rancati T, Rattay T, Reyes V, Rosenstein B, De Ruysscher D, Sperk E, Stobart H, Talbot C, Vega A, Taboada-Valladares B, Veldeman L, Ward T, Webb A, West C, Chang-Claude J, Seibold P; REQUITE Consortium. Rosas JC, et al. Int J Cancer. 2023 Nov 1;153(9):1579-1591. doi: 10.1002/ijc.34640. Epub 2023 Jul 5. Int J Cancer. 2023. PMID: 37403702
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez-Caamaño A, Vega A, Sosa-Fajardo P, Taboada-Valladares B, Aguado-Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Symonds RP, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruysscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang-Claude J, Seibold P, West C, Janelsins M, Chen Y, Messing E, Morrow G; REQUITE Consortium. Kerns SL, et al. Radiother Oncol. 2022 Mar;168:75-82. doi: 10.1016/j.radonc.2022.01.014. Epub 2022 Jan 22. Radiother Oncol. 2022. PMID: 35077710 Free PMC article.
External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort.
Rattay T, Seibold P, Aguado-Barrera ME, Altabas M, Azria D, Barnett GC, Bultijnck R, Chang-Claude J, Choudhury A, Coles CE, Dunning AM, Elliott RM, Farcy Jacquet MP, Gutiérrez-Enríquez S, Johnson K, Müller A, Post G, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, de Santis MC, Sperk E, Stobart H, Symonds RP, Taboada-Valladares B, Vega A, Veldeman L, Webb AJ, West CM, Valdagni R, Talbot CJ; REQUITE consortium. Rattay T, et al. Front Oncol. 2020 Oct 30;10:575909. doi: 10.3389/fonc.2020.575909. eCollection 2020. Front Oncol. 2020. PMID: 33216838 Free PMC article.
A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.
Massi MC, Gasperoni F, Ieva F, Paganoni AM, Zunino P, Manzoni A, Franco NR, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Symonds PR, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Avuzzi B, Giandini T, Valdagni R, Cicchetti A, Azria D, Jacquet MF, Rosenstein BS, Stock RG, Collado K, Vega A, Aguado-Barrera ME, Calvo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T. Massi MC, et al. Front Oncol. 2020 Oct 15;10:541281. doi: 10.3389/fonc.2020.541281. eCollection 2020. Front Oncol. 2020. PMID: 33178576 Free PMC article.
The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol.
Courtney A, O'Connell R, Rattay T, Kim B, Cutress RI, Kirwan CC, Gandhi A, Fairbrother P, Sharma N, Cartlidge CWJ, Horgan K, McIntosh SA, Leff DR, Vidya R, Potter S, Holcombe C, Copson E, Coles CE, Dave RV. Courtney A, et al. Int J Surg Protoc. 2020;24:1-5. doi: 10.1016/j.isjp.2020.07.003. Epub 2020 Jul 29. Int J Surg Protoc. 2020. PMID: 32838092 Free PMC article.
Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction.
Potter S, Trickey A, Rattay T, O'Connell RL, Dave R, Baker E, Whisker L, Skillman J, Gardiner MD, Macmillan RD, Holcombe C; TeaM and iBRA-2 Steering Groups, the Breast Reconstruction Research Collaborative, and the Mammary Fold Academic and Research Collaborative. Potter S, et al. Br J Surg. 2020 Jun;107(7):832-844. doi: 10.1002/bjs.11468. Epub 2020 Feb 19. Br J Surg. 2020. PMID: 32073654
The Pre-BRA (pre-pectoral Breast Reconstruction EvAluation) feasibility study: protocol for a mixed-methods IDEAL 2a/2b prospective cohort study to determine the safety and effectiveness of prepectoral implant-based breast reconstruction.
Harvey KL, Mills N, White P, Holcombe C, Potter S; Pre-BRA Feasibility Study Steering Group. Harvey KL, et al. BMJ Open. 2020 Jan 26;10(1):e033641. doi: 10.1136/bmjopen-2019-033641. BMJ Open. 2020. PMID: 31988232 Free PMC article.
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium. Seibold P, et al. Radiother Oncol. 2019 Sep;138:59-67. doi: 10.1016/j.radonc.2019.04.034. Epub 2019 May 27. Radiother Oncol. 2019. PMID: 31146072 Free article.
16 results